Pacira BioSciences, Inc. (PCRX) shares are seeing an uptick in after-hours trading following the announcement of positive 104-week safety and efficacy data for PCRX-201, a treatment for moderate to severe osteoarthritis of the knee. This long-term data supports the potential of PCRX-201 as a viable option for patients suffering from this condition, which could enhance the company's market position in the osteoarthritis treatment space.
Additionally, Pacira was awarded a new U.S. patent for the composition of EXPAREL, a non-opioid pain management product. This patent strengthens Pacira's intellectual property portfolio, potentially providing a competitive edge in the pain management market.
Pacira BioSciences, Inc. (PCRX) shares rose 0.49% to $19.30 in after-hours trading, following a 1.16% increase to close at $19.20 on December 23, 2024.